Background: Epidemiologic observations have linked healthy dietary patterns to improved kidney function. Study Design: We assessed the effects of the Mediterranean diet (MedDiet) on kidney function in both a cross-sectional assessment and after a 1-year intervention in a cohort of the PREDIMED (Prevención con Dieta Mediterránea) Study, a multicenter 3-arm randomized clinical trial to determine the efficacy of the MedDiet on primary cardiovascular prevention.
C
hronic kidney disease (CKD) is a worldwide public health problem due to an increase in both incidence and prevalence in the last decades. [1] [2] [3] The NKF-KDOQI (National Kidney Foundation's Kidney Disease Outcomes Quality Initiative) defined CKD as kidney damage usually signaled by the presence of albuminuria and/or decreased kidney function.
4,5 A low estimated glomerular filtration rate (eGFR) and albuminuria are independent predictors of major cardiovascular events and mortality. 6, 7 Moreover, current evidence suggests that traditional cardiovascular risk factors, such as advanced age, 8 hypertension, 9 ,10 type 2 diabetes, 11 obesity, 12 and increased circulating levels of peripheral inflammatory markers, 13 are associated with progression of kidney disease.
Of the lifestyle factors, diet appears to have an important role in the prevention and development of CKD. 14 The potential effect of diet on kidney function is attributable in part to its ability to modulate cardiovascular risk factors involved in the development and persistence of decreased kidney function. Some nutritional factors or dietary patterns have been implicated in the progression of kidney disease. [15] [16] [17] [18] [19] However, no specific dietary pattern able to prevent or ameliorate CKD has been recognized by high-level evidencebased studies.
Three cross-sectional studies 18, 20, 21 and 1 prospective investigation 22 have examined the association between dietary patterns and risk of microalbuminuria or decrease in kidney function. All these epidemiologic studies, conducted in apparently healthy young or middle-aged individuals from different populations, showed that greater adherence to healthy dietary patterns, including the Mediterranean diet (MedDiet), was associated inversely with microalbuminuria or decreasing kidney function.
Because results of epidemiologic studies cannot firmly establish causal relationships, intervention studies may help provide a greater degree of scientific evidence for whether a given dietary pattern is associated with changes in kidney function. The aim of the present study was to examine, in the framework of the PREDIMED (Prevención con Dieta Mediterránea) trial, whether the traditional Mediterranean dietary pattern was able to improve kidney function in comparison to a control low-fat diet in an elderly population with multiple cardiovascular risk factors.
METHODS

Study Design and Population
In the present study, we conduct both a cross-sectional and a longitudinal assessment of participants from the Reus-Tarragona area (Spain) who had undergone at least 1 year of follow-up in the PREDIMED trial at the time of analysis. The PREDIMED Study is a large, parallel-group, randomized, multicenter, controlled, 4-year clinical trial aimed to assess the effect of the MedDiet on the primary prevention of cardiovascular disease (www.predimed.org; www.predimed.es). The design of the PREDIMED trial has been reported in detail elsewhere.
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Eligible participants were community-dwelling men aged 55-80 years and women aged 60-80 years who were free of cardiovascular disease at baseline and fulfilled at least one of the following 2 criteria: type 2 diabetes mellitus and/or the presence of 3 or more coronary heart disease risk factors: Family history of early-onset coronary heart disease (before age 55 years in men or before age 65 years in women) in first-degree relatives, current smoking, obesity or overweight (body mass index Ն25 kg/m 2 ), hypertension (blood pressure Ͼ140/90 mm Hg or treatment with antihypertensive medication), or dyslipidemia, with at least one of the following: hypercholesterolemia (low-density lipoprotein cholesterol Ն160 mg/dL), low plasma high-density lipoprotein cholesterol level (Յ40 mg/dL in men or Յ50 mg/dL in women), or treatment with lipid-modulating agents. Exclusion criteria included history of cardiovascular disease, any severe chronic illness, alcohol or drug addiction, history of food allergy or intolerance to olive oil or nuts, or low predicted likelihood of changing dietary habits according to the stages-of-change model. 24 All participants provided informed consent to a protocol approved by the ethical committees of Clinical Investigation of the Sant Joan University Hospital (Reus, Spain) and the Jordi Gol i Gurina Foundation.
Randomization and Intervention
Eligible candidates were invited to attend a screening visit that included a face-to-face interview with an investigator and administration of a 26-item questionnaire to inquire about medical conditions and risk factors related to eligibility. After the screening visit, participants were randomly assigned by means of a computergenerated random-number sequence to 1 of the 3 PREDIMED dietary interventions: a MedDiet supplemented with virgin olive oil (MedDiet ϩ olive oil), a MedDiet supplemented with mixed nuts (MedDiet ϩ nuts), or a control low-fat diet.
A behavioral intervention promoting the MedDiet was implemented in both MedDiet groups, as described. 23 In brief, on the basis of the initial assessment of individual scores of adherence using a 14-item questionnaire, 25 dietitians gave personalized dietary advice to participants randomly assigned to both MedDiet groups, with instructions directed to scale up the score, including, among others (1) abundant use of olive oil for cooking and dressing; (2) increased consumption of fruit, vegetables, legumes, and fish; (3) reduction in total meat consumption, recommending white meat instead of red or processed meat; (4) preparation of homemade sauce with tomato, garlic, onion, and spices with olive oil to dress vegetables, pasta, rice, and other dishes; (5) avoidance of butter, cream, fast food, sweets, pastries, and sugar-sweetened beverages; and (6) for alcohol drinkers, moderate consumption of red wine.
At baseline and every 3 months, dietitians administered both individual interviews and group sessions with a maximum of 20 participants, separately for each group. Sessions consisted of informative talks and delivery of written material with detailed descriptions of typical foods for each dietary pattern, seasonal shopping lists, meal plans, and recipes. Participants assigned to MedDiet groups were given free allotments of either virgin olive oil (15 L every 3 months) or mixed nuts (30 g/d; 15 g/d of walnuts, 7.5 g/d of almonds, and 7.5 g/d of hazelnuts). Participants randomly assigned to the control diet received recommendations to reduce all types of fat intake, from both animal and vegetable sources, as recommended by the American Heart Association guidelines. 26 To encourage adherence, small nonfood gifts, such as kitchenware, tableware, aprons, or shopping bags, were given. Energy restriction was not advised and physical activity was not promoted.
Measurements
At baseline and after 1 year of follow-up, we administered: (1) a 47-item questionnaire about education, lifestyle, history of illnesses, and medication use; (2) a validated semiquantitative 137-item food frequency questionnaire 27 to determine energy and nutrient intake using Spanish food composition tables 28 ; (3) a validated Spanish version of the Minnesota Leisure Time Physical Activity Questionnaire 29 to evaluate physical activity; and (4) a 14-point Mediterranean Diet Adherence Screener (MEDAS) to assess the degree of adherence to the MedDiet (values of 0 or 1 were assigned to each of 14 items; minimum score ϭ 0, maximum score ϭ 14). 25 In addition, anthropometric variables and blood pressure were measured. Waist circumference was measured midway between the lowest rib and the iliac crest. Blood pressure was measured in triplicate using a validated semiautomatic oscillometer with a 5-minute interval between each measurement (Omron HEM-705CP; www.omron-healthcare.com/en/index.html), following the procedures recommended by the European Hypertension Society. 30 All measurements were performed by trained professionals.
At baseline and after intervention for 1 year, blood and urine samples were obtained after an overnight fast. Aliquots of serum, EDTA plasma, and urine were immediately prepared, coded, and sent to a central laboratory and frozen at Ϫ80°C until analysis. Serum glucose, cholesterol, and triglycerides were measured using standard enzymatic automated methods. High-density lipoprotein cholesterol was measured by a precipitation technique. In a random sample of PREDIMED participants, we measured urinary tyrosol and hydroxytyrosol (n ϭ 600) by gas chromatographymass spectrometry as markers of adherence to olive oil intake recommendations, 31 and the proportion of plasma ␣-linolenic acid (n ϭ 571), by gas chromatography as a measure of adherence to nut (walnut) intake guidance.
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Assessment of Kidney Function
Serum urea and creatinine concentrations were determined by enzymatic reaction with urease and by the modified Jaffé colorimetric method, respectively. Urinary creatinine and albumin concentrations were measured using the modified Jaffé colorimetric method and the bromcresol green albumin method, respectively. Total coefficients of variation were Ͻ3.5% for serum urea, Ͻ4.0% for serum creatinine, Ͻ3.0% for urinary creatinine, and Ͻ10.0% for urinary albumin. All analyses were performed using a Roche Hitachi Modular DDP clinical analyzer system (Roche Diagnostics, www.roche.es/portal/roche-spain/diagnostics). Urinary albumin-creatinine ratio (ACR; albumin was measured in milligrams per liter, and creatinine, in milligrams per deciliter) was calculated and reported in milligrams per gram. Microalbuminuria was defined as ACR of 30-300 mg/g, and macroalbuminuria, ACR Ͼ300 mg/g regardless of sex. Based on serum creatinine measurements, GFR was estimated (eGFR) by the CKD-EPI (CKD Epidemiology Collaboration) equation for whites 33 as a measure of kidney function, as described next. For women, for serum creatinine level Ͻ0.7 mg/dL (Ͻ62 mmol/L), eGFR (mL/min/1.73 m 2 ) ϭ 144 ϫ (serum creatinine in mg/dL/0.7)
Ϫ0.329 ϫ (0.993 age ); for serum creatinine level Ͼ0.7 mg/dL (Ͼ62 mmol/L), eGFR (mL/min/1.73 m 2 ) ϭ 144 ϫ (serum creatinine in mg/dL/0.7) Ϫ1.209 ϫ (0.993 age ). For men, for serum creatinine level Ͻ0.9 mg/dL (Ͻ80 mmol/L), eGFR (mL/min/1.73 m 2 ) ϭ 141 ϫ (serum creatinine in mg/dL/ 0.9) Ϫ0.411 ϫ (0.993 age ); for serum creatinine level Ͼ0.9 mg/dL (Ͼ80 mmol/L), eGFR (mL/min/1.73 m 2 ) ϭ 141 ϫ (serum creatinine in mg/dL/0.9) Ϫ1.209 ϫ (0.993 age ).
Statistical Analyses
Categorical variables are presented as percentages. Descriptive data for quantitative variables are presented as mean Ϯ standard deviation or mean and 95% confidence interval or median (25th-75th percentiles). Data were tested first for normal distribution using the Kolmogorov-Smirnov test. Because values for kidney function markers were skewed, values were log-transformed before analysis. Baseline differences among the 3 interventional groups were tested by 2 test for categorical variables or analysis of variance for continuous variables. P value for comparison of geometric mean values between markers of kidney function and degree of adherence to the MedDiet (categorized into quartiles) by group and between groups of intervention were determined by using analysis of covariance adjusted for potential confounders. Bonferroni post hoc test was used to correct for multiple comparisons. Within-group changes between baseline and 1-year measurements were analyzed using paired t tests. Changes between intervention groups were assessed using analysis of covariance with adjustment for potential confounders. All statistical tests were 2 tailed and the significance level was set at P Յ 0.05. Analyses were performed using SPSS software, version 17.0 (SPSS Inc, www01.ibm.com/software/ analytics/spss).
RESULTS
Of 1,125 eligible participants, 870 fulfilled inclusion criteria and entered the trial. Lack of baseline biochemical data limited the cross-sectional analysis to 785 participants (55% women; mean age, 67 years). For the longitudinal analysis, 665 participants (56% women; mean age, 67 years) were available after losses to follow-up and exclusion of those lacking biochemical data (Fig 1) . Clinical characteristics of 120 participants excluded at 1 year were similar to those of completers.
Baseline characteristics of study participants by dietary intervention group are listed in Table 1 . Overall, 93%, 85%, and 54% of participants had overweight/obesity, hypertension, or diabetes mellitus, respectively. No differences among the 3 diet groups were observed in relation to age, sex, weight, body mass index, prevalence of cardiovascular risk factors, or use of medication potentially affecting kidney function. Mean blood urea, serum creatinine, urinary albumin, ACR, and eGFR values also were similar among groups. As listed in Table 2 , there were no significant baseline differences overall or by sex in markers of kidney function by quartiles of adherence to the MedDiet after adjusting for potential confounders.
Energy intake and consumption of selected nutrients and minerals during the intervention in the 665 participants with 1-year data are listed in Table 3 . No significant between-group differences existed in baseline energy intake or nutrient or mineral consumption. Significant differences in changes among groups were observed in relation to total energy as fat, type of fat (saturated, monounsaturated, and polyunsaturated), magnesium, and phosphorus. A significant increase in fat intake occurred in both MedDiet groups, whereas fat consumption decreased in the control group. The increased fat intake in the MedDiet groups was due to increased intake of polyunsaturated and monounsaturated fats, attributable in part to supplementation with olive oil and nuts in the respective treatment arms. Participants assigned to both MedDiet groups also decreased saturated fat intake and increased magnesium and phosphorus intake compared with those allocated to the control group. MEDAS score, which measures adherence to the MedDiet, increased substantially in the 2 MedDiet groups (1.68 Ϯ 2.09 in the MedDiet ϩ olive oil group and 1.83 Ϯ 2.00 in MedDiet ϩ nut group; both P Ͻ 0.001), whereas it increased marginally in the control group (0.65 Ϯ 2.16; P Ͻ 0.01). Urinary tyrosol and hydroxytyrosol levels increased from baseline in participants assigned to the MedDiet ϩ olive oil group (P ϭ 0.05), whereas those assigned to MedDiet ϩ nuts showed a nonsignificant increase in plasma ␣-linolenic acid levels (P ϭ 0.09). No changes were detected in the control group in relation to urinary tyrosol and hydroxytyrosol levels, whereas a decrease in plasma ␣-linolenic acid level was observed in this group.
The diets were well tolerated and no participant abandoned the study due to adverse effects. Body weight at 1 year was similar to baseline, without between-group differences of Ϫ0.18 Ϯ 2.57, 0.04 Ϯ 2.83, and Ϫ0.14 Ϯ 3.15 kg for the MedDiet ϩ olive oil, MedDiet ϩ nuts, and control diet, respectively (P ϭ 0.7 by analysis of variance). Likewise, there were no significant changes from baseline or between groups in systolic blood pressure: Ϫ2.16 Ϯ 17.28, Ϫ1.19 Ϯ 17.29, and Ϫ4.02 Ϯ 17.31 mm Hg, respectively (P ϭ 0.2 by analysis of variance). Table 4 lists 1-year changes from baseline in kidney function markers (serum urea nitrogen, serum creatinine, ACR, and eGFR) by intervention group, as well as differences in changes among groups. Significant 1-year decreases in serum creatinine concentrations and increases in eGFRs were observed in the 3 intervention groups, whereas urinary ACR increased nonsignificantly in participants allocated to the 2 MedDiet groups. However, no significant between-group differences in changes in kidney function were detected. The same analyses conducted separately for participants with or without diabetes showed similar results among groups (Table S1 , available as online supplementary material). There were no significant differences in between-group changes in kidney function in obese versus nonobese participants (data not shown). Likewise, no between-group changes were observed in individuals with or without eGFR Ͻ60 mL/min/1.73 m 2 . However, 1-year increases in eGFRs were higher in individuals with eGFR Ͻ60 mL/min/ 1.73 m 2 compared with those with eGFR Ͻ60 mL/min/ 1.73 m 2 (Table S2) . Sixteen (7.5%), 10 (4.4%), and 13 (5.8%) participants in the MedDiet ϩ olive oil, MedDiet ϩ nuts, and control diet groups, respectively, developed micro-or macroalbuminuria during follow-up. The number of individuals with regression of micro-or macroalbuminuria also was similar among groups. The incidence of individuals progressing to eGFR Ͻ60 mL/min/1.73 m 2 during follow-up also was similar among groups (2.3%, 2.6%, and 3.6% in the MedDiet ϩ olive oil, MedDiet ϩ nuts, and control diet groups, respectively). Similarly, there were no between-group differences in proportions of individuals with eGFR increases from Ͻ60 mL/min/1.73 m 2 to normal during follow-up (11.2%, 7.5%, and 5.4% in the MedDiet ϩ olive oil, MedDiet ϩ nuts, and control diet groups, respectively).
DISCUSSION
To our knowledge, no prior controlled clinical trial has evaluated the long-term effects of dietary patterns on kidney function. Our randomized nutritional intervention study assessed the 1-year effects of a Mediterranean dietary pattern compared with advice for a low-fat diet on kidney function in a large sample of elderly individuals with multiple cardiovascular risk factors. Although the 3 dietary interventions were associated with improved kidney function, as assessed by eGFR, no significant differences were observed in different kidney function variables among the 3 treatment groups. Changes in nutritional and other factors that are known to affect kidney function, namely protein intake, 15 body weight, 12,34 and blood pressure, 9, 10 were similar among groups. Hence, our results do not support that a high-fat high-unsaturated fat MedDiet is better than a reduced-fat diet in improving kidney function, although a limited number of epidemiologic studies suggest a positive association between adherence to the MedDiet and kidney function. 20, 21 Two cross-sectional studies conducted in apparently healthy Greek populations 20, 21 have reported associations between greater adherence to the MedDiet and kidney function markers. In the 3L (Leontio Lyceum Albuminuria) study in 365 healthy Greek adolescents, individuals with greater adherence to the MedDiet showed reduced albuminuria. 20 In addition, in 3,042 adults of both sexes, a direct association Note: Quartiles based on a 14-point food-item score (score range for each quartile is provided in parentheses). Results expressed as median [25th, 75th percentile]. Conversion factors for units: SUN in mg/dL to mmol/L, ϫ0.357; SCr in mg/dL to mol/L, ϫ88.4; eGFR in mL/min/1.73 m 2 to mL/s/1.73 m 2 , ϫ0.01667. Abbreviations: eGFR, estimated glomerular filtration rate; Q, quartile; SCr, serum creatinine; SUN, serum urea nitrogen; UACR, urinary albumin-creatinine ratio. a P value for comparisons between quartiles of Mediterranean diet score by analysis of covariance. b P value for comparisons between quartiles of Mediterranean diet score in the overall population by analysis of covariance. c Adjusted for age, leisure-time physical activity, weight, systolic blood pressure, type 2 diabetes mellitus (yes/no), and angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and statin medication use.
d Adjusted for sex, age, leisure-time physical activity, weight, systolic blood pressure, type 2 diabetes mellitus (yes/no), and angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and statin medication use.
e Adjusted for leisure-time physical activity, weight, systolic blood pressure, type 2 diabetes mellitus (yes/no), and angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and statin medication use. a P value for differences from baseline by paired t test. b P value for differences between groups by analysis of covariance adjusted for sex, age, and total energy intake. c P Ͻ 0.05 for differences between MedDiet ϩ olive oil and control diet group. d P Ͻ 0.05 for differences between MedDiet ϩ olive oil and MedDiet ϩ nuts group. e P Ͻ 0.05 for differences between MedDiet ϩ nuts and control diet group.
between adherence to the Mediterranean dietary pattern and creatinine clearance rate also was shown.
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In contrast to these results, in our study, we found no significant associations between adherence to the MedDiet and several variables of kidney function. That our study group was made up of older individuals at high cardiovascular risk compared with healthy young or middle-aged individuals in prior studies might explain in part the discrepant findings. More importantly, the cross-sectional design of the 2 previous studies with the potential for reverse-causation bias makes them not directly comparable with our results in a randomized trial. The association between dietary patterns different from the MedDiet and renal outcomes recently has been reported from the large prospective Nurses' Health Study (NHS). 22 In that study, women in the top quartile of the DASH (Dietary Approach to Stop Hypertension) adherence score had a nearly 40% decreased risk of rapid eGFR decrease compared with those in the reference quintile during the 11-year follow-up. However, no association was shown for microalbuminuria. In contrast, in the same study, adherence to a Western dietary pattern was associated with significantly increased odds of microalbuminuria and rapid kidney function decrease. 22 Additionally, in MESA (Multi-Ethnic Study of Atherosclerosis), a dietary pattern rich in whole grains, fruit, and low-fat dairy foods was associated significantly with lower urinary ACR. 18 In contrast to our findings of a lack of association of kidney function with increasing adherence to the MedDiet, results of the NHS 22 and MESA 18 support the notion that increasing adherence to a healthy dietary pattern can improve kidney function and decrease the risk of renal deterioration. However, they are consistent with the amelioration of kidney function observed after 1 year of reinforcing healthy dietary patterns, either MedDiet or a low-fat diet, in our clinical trial. It has been proposed 20, 21 that the putative association between adherence to the MedDiet and improved kidney function might be explained by the known effects of this dietary pattern and its components on several cardiometabolic risk markers, such as improved plasma lipid profiles, blood pressure and insulin sensitivity, and decreased oxidative stress, inflammation, and endothelial dysfunction. [35] [36] [37] [38] Although the MedDiets used in the PREDIMED Study have shown their potential to improve both cardiovascular risk biomarkers 37,39 and cardiometabolic outcomes 40, 41 in comparison to the control diet, we could not show that they were superior to improve kidney function. Because the decrease in kidney function usually takes many years, 1 the duration of our study (1 year) might not have been enough to detect a specific benefit of the MedDiet. Future trials with longer follow-up are needed to confirm the hypothesis that the MedDiet may be superior to other dietary interventions to improve kidney function.
Besides the limited duration of follow-up, our study has other limitations. First, the study sample consisted of older Mediterranean white individuals at high risk of coronary heart disease, which prevents generalization of results to other age groups or ethnicities. Second, kidney function markers were determined at baseline and 1 year of intervention only once, and the known biological variability of these measurements may have led to some degree of misclassification. However, measurements were done in a core laboratory, thus reducing variability. Third, in our study, mean eGFR at baseline was fairly high compared with other healthy populations, 42 which may have precluded the observation of clinically significant changes in kidney parameters and limited the number of clini- a P value for differences from baseline by paired t test. b P value for differences between groups by analysis of covariance. c Values were adjusted for sex, age, baseline measure, baseline leisure-time physical activity, and changes in weight, systolic blood pressure, fasting glucose level, and angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and statin medication use.
d Values were adjusted for baseline measure, baseline value physical activity in leisure time, and changes in weight, systolic blood pressure, fasting glucose level, and angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and statin medication use.
cal outcomes. Fourth, many of our patients were using drugs that have a direct effect on kidney function. To minimize this effect, we adjusted our analyses by the use of medication with known effects on kidney function. Fifth, unfortunately, we did not directly measure GFR from creatinine clearance rate. Finally, the equation used to estimate GFR has not been validated in obese people at high cardiovascular risk; thus, it may not be the most appropriate for our population.
In conclusion, our study did not provide enough evidence to support a superiority of one diet over another. Absence of evidence does not mean evidence of no effect. 43 Only equivalence trials are properly suited to demonstrate equality of effects. Nuts SA (Reus, Spain) donated the olive oil, walnuts, almonds, and hazelnuts, respectively, used in the PREDIMED Study. None of the funding sources had a role in the design, collection, analysis, or interpretation of data or in the decision to submit the manuscript for publication. CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn) is an initiative of ISCIII.
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